Glaxo Seeks Indian Consumer Growth, Expanded Capacity
This article was originally published in The Tan Sheet
Executive Summary
GSK hopes to grow in all three of its business areas – consumer healthcare, pharmaceuticals and vaccines – in India with product introductions and a strategy to expand further into rural markets. CEO Andrew Witty previously headed Glaxo’s Asia Pacific operations and says he is a “huge bull on India.”
You may also be interested in...
Glaxo Keeps Alli As Recently Pruned Consumer Division Thrives
GlaxoSmithKline abandons its attempt to divest the OTC weight loss aid alli, even though the beleaguered brand continues to drag down consumer division sales. The division’s sales climbed 7% excluding alli in the firm’s second quarter, but only 5% including the product’s results.
Need For A Vaccines Unit In India Pushes GSK Closer To Align With India's Biological E; Is A Buyout Imminent ?
MUMBAI - GlaxoSmithKline Plc.'s vaccines arm, the Belgium-headquartered GSK Biologicals S.A. is believed to be on course to acquire Hyderabad, India-based vaccines manufacturer Biological E. Ltd., a report in The Economic Times said last week. If the deal comes to fruition, GSK would fulfil its long desire to buy an Indian asset that could be leveraged for its expanding network in the high potential emerging markets
GSK India Managing Director Hasit Joshipura On Business Dynamics In India, Tiered Pricing And Approaches To Rural Markets: An Interview With PharmAsia News (Part 2 Of 2)
Hasit Joshipura, GlaxoSmithKline's India Managing Director is unfazed by the recent mega-deal that Abbott struck with Piramal Healthcare - catapulting the U.S. giant to the number one slot in India with a market share of nearly 7 percent.